Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anhydrous enol oxaloacetate - MetVital

Next Previous
Drug Profile

Anhydrous enol oxaloacetate - MetVital

Alternative Names: AEO; Anhydrous Enol-Oxaloacetate; Anhydrous enol-oxaloacetate - MetVital; Oxaloacetate; Oxaloacetate CFS

Latest Information Update: 06 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MetVital
  • Developer MetVital; Terra Biological
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Nootropics; Oxaloacetates; Small molecules
  • Mechanism of Action Oxaloacetate replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Glioblastoma; Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Cognition disorders; Fatigue; Glioblastoma
  • Preclinical Liver cancer
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 01 Jun 2023 Phase-II clinical trials in Fatigue in USA (unspecified route) (NCT05840237)
  • 28 Jan 2023 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in USA
  • 25 Jan 2023 Phase-II clinical trials in Alzheimer's disease in USA (PO) (MetVital pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top